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Abstract
Background: Enzalutamide is an androgen receptor inhibitor with a demonstrated overall survival
benefit in metastatic castration-resistant prostate cancer. A phase 2 study of enzalutamide mono-
therapy in patients with hormone-naı¨ve prostate cancer (HNPC) showed a high response rate for the
prespecified primary endpoint (ie, prostate-specific antigen [PSA] response [8_TD$DIFF]at week 25), regardless of
metastases at baseline, and favorable tolerability.
Objective: To determine the long-term efﬁcacy and safety of enzalutamidemonotherapy at 1 and 2 yr.
Design, setting, and participants: Open-label, single-arm study in patients with HNPC and nonca-
strate testosterone (230 ng/dl).
Intervention: Oral enzalutamide 160 mg/d until disease progression or unacceptable toxicity.
Outcome measurements and analysis: PSA response (80% decline from baseline) assessed at 1 yr
(49 wk) and 2 yr (97 wk).
Results and limitations: Themedian (range) agewas73 (48–86)yr and26patients (39%)presentedwith
metastases at study entry. Of 67 patients enrolled, 45 (67%) remained on enzalutamide [8_TD$DIFF] at week 97. For
patients remaining on therapy, the PSA response rate [8_TD$DIFF] at week 97was 100% (95% conﬁdence interval 92–
100%). Of 26 patientswithmetastases at baseline, 13 (50%) had a complete and four (15.4%) had a partial
responseasbestoverall tumorresponseupto97wkontreatment.Therewasoverallmaintenanceof total-
body bonemineral density (BMD) andmoderate changes in lean and fat bodymass at 49 and 97wk. The
most common adverse events were gynecomastia, nipple pain, fatigue, and hot ﬂushes. The study
limitations include lack of a control group and of endocrine, glycemic, and lipid data at 97 wk.
Conclusions: Long-term enzalutamide monotherapy in men with noncastrate HNPC is associated
with large sustained reductions in PSA, signals indicating a favorable tumor response, and favorable
safety/tolerability proﬁle, with relatively small negative effects on total-body BMD.
Patient summary: In this long-term follow-up of the efﬁcacy and safety of enzalutamide mono-
therapy in patients with hormone-naı¨ve prostate cancer, enzalutamide maintained long-term
reductions in prostate-speciﬁc antigen, with a minimal impact on total-body bone mineral density.
Trial registration: NCT01302041
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Androgen deprivation therapy (ADT) is the current standard
of care for advanced prostate cancer [1]. Nonsteroidal
androgen receptor (AR) inhibitors, or antiandrogens, offer
an alternative treatment strategy to ADT with different side
effects, inhibiting ARs while maintaining or increasing
testosterone [2]. It has been shown that treatment of locally
advanced prostate cancer with high-dose bicalutamide
monotherapy provides equivalent overall survival benefits
and different toxicity than ADT, with fewer castration-
associated symptoms [3–6].
Enzalutamide is an oral AR [1 6 _ TD $ D I FF ] signaling inhibitor appro-
ved [ 1 7_ T D $D I F F] in the United States for the treatment of [ 1 8 _T D $ DI F F ]patients with
metastatic castration-resistant prostate cancer (mCRPC) [ 19 _ T D$ D I FF ]
and in the EU for the treatment of asymptomatic or mildly
symptomatic men with mCRPC after failure of androgen
deprivation therapy in whom chemotherapy is not yet
clinically indicated, or those whose disease has progressed
on or after docetaxel therapy [7]. Enzalutamide has
greater affinity for the AR compared with bicalutamide
[8] and its mode of action is distinct in that it inhibits
nuclear translocation of the AR, DNA binding, and
coactivator recruitment [9]. In an early trial, enzalutamide
demonstrated antitumor effects irrespective of chemo-
therapy status [10]. In the subsequent phase 3 AFFIRM
trial, enzalutamide significantly prolonged the survival of
men with mCRPC after docetaxel chemotherapy and
showed favorable results for all secondary endpoints
[11]. More recently, enzalutamide significantly improved
overall survival in men with chemotherapy-naı¨ve mCRPC
in the phase 3 PREVAIL trial [12]. Clinical studies of
enzalutamide have largely been in castrate men (main-
tained on a luteinizing hormone-releasing hormone
[LHRH] analog or after surgical castration) with prior
and continued hormone treatment. On the basis of its
mode of action, there is a strong rationale for evaluation of
enzalutamide in noncastrate men with hormone-naı¨ve
prostate cancer (HNPC). We previously reported 25-wk
results of a phase 2, open-label, single-arm study of
enzalutamide monotherapy in noncastrate men with
HNPC at any disease stage eligible for ADT [13]. Enzalu-
tamide monotherapy for 25 wk resulted in a prostate-
specific antigen (PSA) decline of 80% in 92.5% of patients
and was generally well tolerated [13]. We now report
follow-up data describing the long-term efficacy, safety,
and tolerability of enzalutamide monotherapy after 1-yr
and 2-yr treatment periods.
2. Patients and methods
The study methods have previously been described in detail [13]. In
brief, this phase 2, open-label, single-arm study (NCT01302041) across
12 European sites investigated the efﬁcacy, safety, and tolerability of
enzalutamide in patients with HNPC and noncastrate testosterone levels
(230 ng/dl). The cutoff dates for the 1-yr (49 wk) and 2-yr (97 wk)
follow-up periods were December 28, 2012 and December 28, 2013,
respectively. The protocol was approved by local institutional review
boards and independent ethics committees and authorities. Participants
provided written informed consent before study entry.
2.1. Procedures
Patients received enzalutamide (160 mg/d orally) until disease progres-
sion or unacceptable toxicity occurred. Patients discontinued therapy in
the event of objective or clinical disease progression, including PSA
progression deﬁned as a 50% increase from nadir that was 5 ng/ml,
conﬁrmed at least 2 wks later, or the development of an adverse event
(AE) or toxic effect for which continued administration of the study drug
was deemed not to be in the patient’s best interest.
Blood sampleswere taken tomeasure PSA and hormone levels. PSAwas
assessedonday1, [8_TD$DIFF] atweeks 2 and5, and every 4wk thereafter untilweek25,
and thenevery12wk thereafter.Hormone levelswere assessedevery12wk
until week 49 (1 yr). Fasting serum lipids, insulin, and glucose levels were
measured in samples collected on day 1 and [8_TD$DIFF] at weeks 13, 25, and 49.
Bonemass density (BMD) and lean and fat bodymassweremeasured
by dual-energy x-ray absorptiometry scans [8_TD$DIFF]at weeks 1 and 25, and at
subsequent 24-wk intervals up to and including week 97.
Abdominopelvic computerized tomography or magnetic resonance
imaging and a bone scanwere carried out at study entry. If metastaseswere
identiﬁed, imaging was performed [8_TD$DIFF] at week 25 or on discontinuation (if
earlier), and at subsequent 24-wk intervals, up to and including week 97.
Health-related quality of life was assessed using the self-administered
European Organisation for Research and Treatment of Cancer core quality-
of-life questionnaire (EORTC QLQ-C30) and quality-of-life questionnaire for
patientswith prostate cancer (EORTCQLQ-PR25) [14,15] on day 1, inweeks
13and25, and thenevery24wkuptoand includingweek97.Health-related
quality-of-life data (speciﬁcally, sexual functioning and sexual activity as
measured by the EORTC QLQ-PR25) are only reported in brief here and will
be presented fully in a separate publication. AEswere recorded at each clinic
visit and graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 4.0 [16].
2.2. Outcomes
The primary outcome was PSA response deﬁned as a decline in PSA level
from baseline of80%. Prespeciﬁed secondary and exploratory outcomes
includedobjective andbest overall tumor response, and changes in fasting
serumlipids, insulin sensitivity, BMD,and leanandfatbodymass. Levelsof
PSA decline by metastatic status at study entry were also investigated.
Safety measures included reporting of discontinuations and AEs.
2.3. Statistical analyses
Sample size calculations were based on the primary endpoint of PSA
response assessed [ 8 _ TD $ D IF F ]at week 25 [13]. With a sample size of 47 patients,
the study had 80% power to reject a PSA response rate of 50% at a 5%
signiﬁcance level, with an expected 70% response for enzalutamide. A
total patient number of 60 was planned to allow for a 20% dropout rate.
PSA response rates were calculated as the number of patients with a
80% PSA decline from baseline at a given time point, divided by the
number of patients who started treatment (patients who discontinued
before the timepointwere considered nonresponders) or the number of
patients remaining on treatment at the time point. Corresponding 95%
conﬁdence intervals (CIs) were calculated based on the exact binomial
distribution. All patients who received at least one dose of the study
drug were included in the analysis. Demographics, secondary out-
comes, and safety variables were summarized descriptively. The
objective tumor response was calculated in patients with measurable
disease at study entry. Amixed-model repeated-measures analysiswas
used to assess changes in sexual functioning and sexual activity from
baseline to 49 and 97wk. Assessments made at 49wkwere regarded as
the 1-yr results and those at 97wkas the 2-yr results. AEswere reported
per calendar year of treatment. Data were analyzed using SAS version
9.2 or later.
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3. Results
Sixty-seven patients enrolled in the study and received at
least one dose of study drug. All patients were included in
the safety population. Data on baseline demographics and
medical disease history are presented in Table 1. The
median (range) age of patients was 73 (48–86) yr and the
duration of disease ranged from 0 to 16 yr. Overall, 39% of
patients presented with metastases at study entry; 36% had
previously undergone prostatectomy and 24% had received
radiotherapy. Four patients discontinued treatment before
week 25, as previously described [13]. Five additional
patients discontinued treatment at the 25-wk visit and four
others before the 49-wk visit, with 54 patients (81%)
remaining on treatment up to week 49. Of the nine patients
who discontinued treatment between 25 and 49 wk, two
patients died (one due to acute myocardial infarction and
one due to cardiorespiratory arrest; neither death was
considered related to treatment or disease progression),
two patients discontinued because of AEs, two discontinued
because of progressive disease, and three withdrew for
therapeutic breaks (cessation of study drug secondary to
improved disease evaluation). Nine additional patients
discontinued treatment at or after week 49: one because of
an AE, five because of progressive disease, and three for
therapeutic breaks. In total, 18 patients discontinued
treatment before or at the 49-wk visit, and four more
during the second year on treatment, with 45 patients
(67.2%) remaining on treatment at and after week 97.
Among all 67 patients who started the study, 81% (95% CI
69–89%) and 67% (95% CI 55–78%) of patients had a PSA
response (80% decline from baseline) at 49 and 97 wk,
respectively. A PSA response at 49 and 97 wk was observed
in all patients remaining on treatment at these time points:
Table 1 – Baseline characteristics for the 67 patients
Parameter Value
Age, yr (range) 73 (48–86)
Body mass index, kg/m2 (range) 26.2 (20.8–39.7)
Prostate-speciﬁc antigen, ng/ml (interquartile range) 18.2 (6.4–45.0)
Duration of prostate cancer, yr (range) 1 (0–16)
Characteristics at initial diagnosis
Total Gleason score, n (%)
6 16 (24)
7 34 (51)
8 16 (24)
Clinical stage of primary tumor, n (%)
T0–T2 41 (61)
T3 18 (27)
T4 1 (2)
TX [6_TD$DIFF]a 7 (10)
Clinical lymph node stage, n (%)
N0 22 (33)
N1 6 (9)
Nx, unknown or not assessed 39 (58)
Distant metastases[7_TD$DIFF], n (%)
M0 35 (52)
M1 10 (15)
Mx, unknown or could not be assessed 22 (33)
Metastases at study entry, n (%) 26 (39)
Number of metastatic lesions by bone scan, n (range) 1 (1–8)
Previous interventions, n (%)
Radiotherapy 16 (24)
Prostatectomy 24 (36)
Transurethral resection of the prostate 4 (6)
Pelvic lymph node dissection 6 (9)
Watchful waiting 14 (21)
a Includes unknown (n = 6) and tumors that could not be assessed (n = 1).
Table reprinted and modiﬁed from The Lancet. Tombal B, Borre M,
Rathenborg P, et al. Enzalutamide monotherapy in hormone-naive
prostate cancer: primary analysis of an open-label, single-arm, phase
2 study. Lancet Oncol 2014;15:592–600 [13] with permission from
Elsevier. # 2014 Elsevier.
Table 2 – PSA outcomes [8_TD$DIFF]at weeks 49 and 97 for patients with and without metastases at screening, and objective and best overall tumor
response rates [8_TD$DIFF]at weeks 49 and 97
Week 49 (54 of 67 patients) Week 97 (45 of 67 patients)
No metastases Metastases No metastases Metastases
(n = 31) (n = 23) (n = 26) (n = 19)
PSA decline 80%, n (%) 31 (100) 23 (100) 26 (100) 19 (100)
PSA decline 90%, n (%) 31 (100) 22 (96) 26 (100) 19 (100)
PSA 4 ng/ml, n (%) 30 (97) 21 (91) 26 (100) 19 (100)
PSA 0.1 ng/ml, n (%) 21 (68) 13 (57) 19 (73) 14 (74)
Response, n (%) a Week 49 Week 97 Best overall response by week 97
(n = 26) b (n = 26) b (n = 26) b
Complete response 7 (27) 12 (46) 13 (50)
Partial response 3 (12) 3 (12) 4 (15)
Non-CR/non-PD 5 (19) 2 (8) 3 (12)
Stable disease 1 (4) 1 (4) 2 (8)
Progressive disease 1 (4) 0 (0) 3 (12)
Not evaluated 6 (23) 1 (4) 1 (4)
Stopped treatment before time point 3 (12) 7 (27) NA
CR = complete response; PD = progressive disease; NA = not applicable; PSA = prostate-speciﬁc antigen.
a Response was assessed using RECIST v1.1 for soft-tissue lesions and The Prostate Cancer Clinical Trials Working Group 2 (PCWG2) for bone lesions.
b Number of patients with metastatic disease at study entry. All patients were assessed for bone and soft-tissue metastases using magnetic resonance imaging
or computed tomography and a bone scan within 28 d before study drug administration.
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54 patients (100%, 95% CI 93–100%) and 45 patients (100%,
95% CI 92–100%), respectively (Fig. 1A).
Among patients who remained on treatment, mean
(standard deviation) PSA levels were 0.54 (1.46) ng/ml at
49 wk and 0.16 (0.36) ng/ml at 97 wk (Fig. 1B). A maximum
PSA decline from baseline of 99–100% by week 97 was
achieved in 55 patients (82%), with a decline of 95–99% in
eight patients (12%) and a decline of at least 86% in the
remaining four patients. These declines were, for the most
part, already observed byweek 25. Among the patients with
assessment available at 49 and 97 wk, PSA was 0.1 ng/ml
in 34 patients (63%) at 49 wk and in 33 patients (73%) at
97 wk. PSA responses were generally comparable at both
follow-up time points for those with and without metasta-
ses (Table 2).
The best overall response up to week 97 was assessed
for the 26 patients who hadmetastases at baseline. Of these,
13 (50%) had a complete response, four (15%) had a partial
response, two (8%) had stable disease, three (12%) had
noncomplete response/nonprogressive disease, three (12%)
had progressive disease, and one (4%) was not evaluated.
Objective tumor responses at 49 and 97 wk are reported in
Table 2.
All hormone levels increased from baseline to 49 wk
(Table 3). The largest increaseswere in luteinizing hormone,
testosterone, and sex hormone–binding globulin levels.
Luteinizing hormone and testosterone levels increased
sharply between 1 and 5 wk, after which luteinizing
hormone continued to rise steadily until 49 wk, while
testosterone leveled off between 13 and 49 wk (Fig. 2).
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Fig. 1 – (A) Mean percentage change in prostate-specific antigen from baseline and (B) mean prostate-specific antigen level by week. Bars show
standard deviation.
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Small to moderate increases were observed across
fasting lipid profiles from baseline to 49 wk (Table 3),
whereas hemoglobin A1c and fasting glucose remained
relatively stable. Moderate increases from baseline to 49wk
were seen for fasting insulin and the homoeostasis model
assessment of insulin resistance (Table 3). Total, spine,
and forearm BMD was generally maintained from baseline
to 97wk, with small decreases (2–3%) in BMD from baseline
measured in the femoral neck and trochanter at 97 wk
(Table 4). Fat body mass increased from baseline to
49 and 97 wk, while lean body mass decreased (Table 4).
Biomarkers of osteoblast activity (bone alkaline
phosphatase) and osteoclast activity (N-telopeptide and
N-telopeptide/creatinine) increased from baseline to 49wk,
and N-telopeptide and N-telopeptide/creatinine increased
from baseline to 97 wk. Bone alkaline phosphatase was not
measured at 97 wk. Clinically meaningful (10.7 points)
reductions in sexual functioning from baseline were
observed at 49 and 97 wk. There were no clinically
meaningful changes in sexual activity (Supplementary
Table 1).
The most frequently reported treatment-emergent AEs
during 2-yr treatment were gynecomastia (49%), fatigue
(39%), nipple pain (21%), and hot flushes (21%) (Supple-
mentary Table 2). AEs of decreased libido and loss of libido
were reported by one patient (2%). There were 471 AEs
reported by 65 patients (97%), of which 229 events (49%)
were considered to be related to enzalutamide. Fifteen
patients reported 31 serious AEs, ofwhich fivewere deemed
to be drug-related: two incidences of atrial fibrillation, one
of arrhythmia, one of tachycardia, and one of chronic fatigue
syndrome. Three patients (5%) discontinued because of
drug-related AEs: one due to fatigue, one due to dizziness,
and one due to asthenia, depression, fatigue, and insomnia.
4. Discussion
This is the first study to investigate the effects of
enzalutamide during 2-yr follow-up in noncastrate men
(no surgical castration or LHRH analog maintenance) with
HNPC, including patients with andwithoutmetastases. This
analysis builds on previously published results showing
that after 25wk of treatment, enzalutamide provided a level
of disease suppression in men with HNPC of varying
severity, asmeasured by large and sustained declines in PSA
Table 3 – Endocrine, lipid, and glycemic outcomes [8_TD$DIFF]at week 49
n Mean change
from baseline, % (SD)
Endocrine outcomes
Testosterone 51 +102 (76)
Dihydrotestosterone 45 +74 (102)
Sex hormone-binding globulin 53 +89 (42)
Dehydroepiandrosterone 51 +11 (55)
Luteinizing hormone 52 +215 (164)
Follicle-stimulating hormone 52 +62 (78)
Androstenedione 51 +50 (55)
Prolactin 53 +10 (30)
Estradiol 52 +81 (83)
Lipid proﬁle
Total cholesterol 36 +5 (20)
High-density lipoprotein cholesterol 36 +6 (14)
Low-density lipoprotein cholesterol 35 +9 (41)
Triglycerides 36 +9 (43)
Glycemic proﬁle
Hemoglobin A1c 32 –4 (4)
Fasting glucose 32 –1 (9)
Fasting insulin 31 +21 (57)
HOMA-IR 31 +20 (56)
[10_TD$DIFF]SD = standard deviation; HOMA-IR = homoeostasis model assessment of
insulin resistance.
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Fig. 2 – Mean percentage change in luteinizing hormone and testosterone from baseline to week 49.
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that were similar to those observed in ADT studies
[13]. Enzalutamide monotherapy was associated with large
and consistent PSA reductions from week 25 through to
week 97 in patients remaining on therapy. Almost three-
quarters of patients (73%) still in the study at 97wk had PSA
0.1 ng/ml; 58% had either a complete or partial tumor
response. PSA responses were comparable for patients with
and without metastases. In patients with measureable
disease at study entry, the best overall objective tumor
response to enzalutamide monotherapy up to week
97 showed that themajority of patients had either complete
or partial responses. Small decreases were observed in
total-body BMD and in lean body mass, while there were
increases in fat bodymass. Therewere clinicallymeaningful
reductions in sexual functioning, but not sexual activity. A
large proportion of patients continued to benefit from
enzalutamide and remained in the study at 97 wk.
Our study sample represents a population of prostate
cancer patients with a range of baseline disease severity,
including patients with localized, locally advanced, and
metastatic disease for whom ADT was indicated. Of
particular note is the finding that almost all patients
remaining on therapy had a PSA reduction of90% at 49 and
97wk. This compares favorably, albeit indirectly, with other
available treatments for prostate cancer. A>90% decrease in
geometric mean PSA levels was observed at 12 wk for
patients who received bicalutamide ranging from 300 to
600 mg (doses above the approved dose of 150 [20_TD$DIFF]mg) or who
were treated by castration [17], although, as with other
bicalutamide studies, these are short-term results. As an
indirect comparison with a contemporary gonadotropin-
releasing hormone (GnRH) analog, the GnRH antagonist
degarelix resulted in a reduction of PSA to a median level of
0.5 ng/ml after 1 yr [18], which wasmaintained at<2 ng/ml
during treatment for up to 5 yr [19]. Further comparisons
are challenging because of sparse data on the long-term
efficacy of primary ADT in terms of PSA response [1].
The Cochrane Collaboration recently published a sys-
tematic review comparing nonsteroidal antiandrogens to
ADT and concluded that nonsteroidal antiandrogens were
inferior in terms of overall survival and clinical progression
[20]. Notably, this conclusion was based on trials using a
range of different dosages of bicalutamide, including three
trials with bicalutamide 50 mg, a dosage that was found to
be ineffective and has not led to subsequent registration of
bicalutamide monotherapy. The activity of bicalutamide
monotherapy was extensively addressed by the European
Medical Agency in 2007 [21] and the recent Cochrane
systematic review does not add any new or relevant
information for clinicians.
Unlike ADT, which reduces levels of male hormones,
enzalutamide acts by inhibiting androgen signaling [9]. This
is reflected in the present study by sustained increases across
all hormonemeasures at 49 wk, most notably for luteinizing
hormone, testosterone, estradiol, and sex hormone–binding
globulin. These findings are consistent with those for other
antiandrogens, for which testosterone and estradiol levels
generally increase following treatment [17,22]. Although
increases in hormone levels were observed throughout the
first year of treatment in the present study, no AE related
to increased hormone levels led to discontinuation. Study
withdrawals because of hormone-related AEs, namely
gynecomastia and breast pain, have been observed for
bicalutamide [3,23,24].
Small decreases in BMD (2–3%) were observed for some
body sites, although the changes are smaller than those
reported for castration, with decreases in femoral BMD of
7–10% [25,26] and lumbar spine of 5% [5]. ADT-related BMD
decreases at 1 and 2 yr have been reported for femoral neck
(BMD decreases of 4% [27] and 10% [25]) and at 1 yr for
lumbar spine (BMD decrease of 3% [28]). The relatively
stable BMD findings in our study may indicate bone-
protective effects due to higher estrogen levels.
Decreases in lean body mass and increases in fat body
mass were observed at 49 and 97 wk, indicating a trend
towards the development of sarcopenic obesity. The changes
observed for enzalutamide suggest that they may be greater
than those observed over 1 yr for bicalutamide [29], and in
line with the more potent antiandrogenic effects seen with
castration over 1 yr [29,30] and 2 yr [5]. These observations
Table 4 – Body composition and bone turnover biomarkers [8_TD$DIFF]at weeks 49 and 97
Baseline Week 49 Week 97
n Mean (SD) n Mean change
from baseline, % (SD)
n Mean change
from baseline, % (SD)
Body composition
Bone mineral density (g/cm2)
Total 50 1.2 (0.1) 36 –0.2 (2.1) 29 –0.4 (2.2)
Femoral neck 50 0.9 (0.2) 41 –0.4 (2.6) 33 –2.2 (3.0)
Trochanter 50 0.8 (0.2) 41 –1 (3) 33 –2.2 (3.7)
Spine L1–L4 51 1.2 (0.2) 40 –0.6 (3.3) 32 –0.6 (4.3)
Forearm (radius 33%) 52 0.8 (0.1) 41 +0.5 (2.7) 31 –0.3 (3.1)
Fat body mass (kg) 50 25 (7) 36 +9 (18) 29 +11 (9)
Lean body mass (kg) 50 57 (7) 36 –4.4 (4) 29 –5.3 (3.7)
Bone turnover biomarkers
Bone alkaline phosphatase (mg/l) 67 11 (6) 53 +12 (32) NA NA
N-telopeptide (nmol/l) 65 334 (177) 52 +62 (120) 39 +36 (90)
N-telopeptide/creatinine
(nmol/mol creatinine)
65 28 (13) 52 + 64 (66) 39 +50 (70)
SD = standard deviation; NA = not available.
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are consistent with what is known about muscle and bone
biology in relation to the effects of agents targeting the AR.
These results are sufficiently encouraging to consider
conducting a larger clinical trial to demonstrate whether
enzalutamide may be used not only in addition to ADT but
also as an alternative approach to AR signaling suppression,
with similar efficacy and amore favorable side-effect profile
compared with ADT. There are, however, challenges to
address, including identifying the most appropriate clinical
setting (locally advanced or metastatic prostate cancer; a
single treatment or adjuvant to radical treatment) and,
more importantly, establishing registration rules with
regulators.
The long-term follow-up and multiple objectively
measured outcomes represent major strengths of this
study. Although positive, its open-label design, lack of
control arm, small sample size, and lack of endocrine,
glycemic, and lipid data [8_TD$DIFF]at week 97 are limitations
warranting caution when interpreting the results.
5. Conclusions
In conclusion, in this open-label 2-yr follow-up, enzaluta-
mide monotherapy treatment in men with noncastrate
HNPCwith or withoutmetastases was associatedwith large
and sustained PSA reductions, signals indicating a favorable
tumor response, and a favorable safety/tolerability profile.
This was achieved with relatively small negative effects on
total-body BMD.
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